Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01460862
Recruitment Status : Unknown
Verified November 2017 by Novartis ( Novartis Pharmaceuticals ). Recruitment status was: Active, not recruiting
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with uncontrolled asthma and using high-dose ICS prior to initiating omalizumab.
≥12 years of age with a documented Cystic fibrosis (CF) diagnosis,
on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline,
uncontrolled asthma at baseline.
Other protocol-defined inclusion/exclusion criteria may apply.